Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Audentes Therapeutics, Inc. (BOLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/31/2022 3 Audentes Therapeutics, Inc. (10% Owner) has filed a Form 3 on Taysha Gene Therapies, Inc.
10/31/2022 SC 13D Audentes Therapeutics, Inc. reports a 11.6% stake in TAYSHA GENE THERAPIES, INC.
02/14/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/11/2020 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/05/2020 SC 13G/A BlackRock Inc. reports a 8% stake in Audentes Therapeutics, Inc.
01/27/2020 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
01/21/2020 EFFECT Form EFFECT - Notice of Effectiveness:
01/21/2020 EFFECT Form EFFECT - Notice of Effectiveness:
01/15/2020 4 Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 183,384 shares @ $60, valued at $11M
Disposed/sold 3,829 options to buy @ $2.7649, valued at $10.6k
Disposed/sold 6,263 options to buy @ $9.4988, valued at $59.5k
Disposed/sold 73,781 options to buy @ $15.26, valued at $1.1M
Disposed/sold 75,000 options to buy @ $27.39, valued at $2.1M
Disposed/sold 65,000 options to buy @ $24.74, valued at $1.6M
01/15/2020 4 Smith Julie (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Disposed/sold 18,000 options to buy @ $17.85, valued at $321.3k
Disposed/sold 9,000 options to buy @ $0
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Schuetz Thomas J. (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 89,695 shares @ $60, valued at $5.4M
Disposed/sold 18,086 options to buy @ $0.7804, valued at $14.1k
Disposed/sold 5,605 options to buy @ $2.1852, valued at $12.2k
Disposed/sold 9,000 options to buy @ $15.03, valued at $135.3k
Disposed/sold 9,000 options to buy @ $0
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 261,458 shares @ $60, valued at $15.7M
Unknown transaction of 171,814 shares @ $60, valued at $10.3M
Disposed/sold 143,569 options to buy @ $9.4988, valued at $1.4M
Disposed/sold 188,334 options to buy @ $15.26, valued at $2.9M
Disposed/sold 225,000 options to buy @ $27.39, valued at $6.2M
Disposed/sold 177,450 options to buy @ $24.74, valued at $4.4M
01/15/2020 4 Mosbrooker Eric (SVP, Chief Commercial Officer) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 26,919 shares @ $60, valued at $1.6M
Disposed/sold 87,750 options to buy @ $22.01, valued at $1.9M
01/15/2020 4 Morrison Scott W (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Disposed/sold 33,635 options to buy @ $9.4988, valued at $319.5k
Disposed/sold 9,000 options to buy @ $15.03, valued at $135.3k
Disposed/sold 9,000 options to buy @ $0
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Meltz Mark A (SVP, General Counsel) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 32,705 shares @ $60, valued at $2M
Disposed/sold 104,000 options to buy @ $37.26, valued at $3.9M
01/15/2020 4 LANGE LOUIS G (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 265,799 shares @ $60, valued at $15.9M
Unknown transaction of 13,678 shares @ $60, valued at $820.7k
Unknown transaction of 32,343 shares @ $60, valued at $1.9M
Unknown transaction of 3,555 shares @ $60, valued at $213.3k
Disposed/sold 18,000 options to buy @ $15.03, valued at $270.5k
Disposed/sold 9,000 options to buy @ $0
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Jarrett Jennifer (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Disposed/sold 18,000 options to buy @ $14.7, valued at $264.6k
Disposed/sold 9,000 options to buy @ $0
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Holles Natalie C. (President and COO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 104,439 shares @ $60, valued at $6.3M
Disposed/sold 110,703 options to buy @ $2.7649, valued at $306.1k
Disposed/sold 548 options to buy @ $9.4988, valued at $5.2k
Disposed/sold 40,883 options to buy @ $15.26, valued at $623.9k
Disposed/sold 93,109 options to buy @ $27.39, valued at $2.6M
Disposed/sold 25,000 options to buy @ $36.39, valued at $909.8k
Disposed/sold 50,105 options to buy @ $24.74, valued at $1.2M
01/15/2020 4 Goldberg Mark Alan (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 1,500 shares @ $60, valued at $90k
Disposed/sold 18,000 options to buy @ $33.91, valued at $610.4k
Disposed/sold 4,500 options to buy @ $38, valued at $171k
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Conner Edward R. (SVP, Chief Medical Officer) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 24,584 shares @ $60, valued at $1.5M
Disposed/sold 90,000 options to buy @ $36.08, valued at $3.2M
01/15/2020 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
01/15/2020 POS AM Form POS AM - Post-Effective amendments for registration statement:
01/15/2020 POS AM Form POS AM - Post-Effective amendments for registration statement:
01/15/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/15/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/15/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/15/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/15/2020 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
01/15/2020 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation of Audentes Therapeutics, Inc",
"Amended and Restated Bylaws of Audentes Therapeutics, Inc",
"Astellas Completes Acquisition of Audentes Therapeutics"
01/15/2020 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
01/15/2020 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
01/10/2020 4 Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Exercised 144,669 options to buy @ $2.7649, valued at $400k
Exercised 6,219 options to buy @ $15.26, valued at $94.9k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy